Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents

Archives of Pediatrics and Adolescent Medicine

Volumn 162, Issue 10, 2008, Pages 916-921

  Wilens, Timothy E ^a   Adamson, Joel ^a   Monuteaux, Michael C ^a   Faraone, Stephen V ^b   Schillinger, Mary ^a   Westerberg, Diana ^a   Biederman, Joseph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOSTIMULANT AGENT;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CIGARETTE SMOKING; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; DRUG EXPOSURE; HUMAN; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SUBSTANCE ABUSE;

ADOLESCENT; ADOLESCENT BEHAVIOR; ALCOHOL-RELATED DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; ATTITUDE TO HEALTH; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; COMORBIDITY; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; SMOKING; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 53849119841     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpedi.162.10.916     Document Type: Article

References (39)

1. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
2. Faraone SV. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2(2):104-113.
3. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942-948.
4. Hinshaw SP. Preadolescent girls with attention-deficit/hyperactivity disorder, I: background characteristics, comorbidity, cognitive, and social functioning, and parenting practices. J Consult Clin Psychol. 2002;70(5):1086-1098.
5. Biederman J, Monuteaux MC, Mick E, et al. Psychopathology in females with attention-deficit/hyperactivity disorder: a controlled, five-year prospective study. Biol Psychiatry. 2006;60(10):1098-1105.
6. Weiss G, ed. Attention-Deficit Disorder: Child and Adolescent Psychiatric Clinics of North America. Philadelphia, PA: WB Saunders Co; 1992.
7. Biederman J, Faraone S, Mick E. Age-dependent decline of ADHD symptoms revisited: impact of remission definition and symptom subtype. Am J Psychiatry. 2000;157(5):816-817.
8. Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/ hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics. 2005;115(6):1734-1746.
9. Pliszka SR, Crismon ML, Hughes CW, et al; Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(6):642-657.
10. Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med. 2006;36(2):167-179.
11. Milberger S, Biederman J, Faraone SV, Chen L, Jones J. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997;36(1):37-44.
12. Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis. 1997;185(8):475-482.
13. Molina BS, Pelham W. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol. 2003;112(3):497-507.
14. Molina BS, Flory K, Hinshaw SP, et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1028-1040.
15. McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry. 2005;162(9):1621-1627.
16. Greenhill LL, Pliszka S, Dulcan MK, et al; American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2)(suppl):26S-49S.
17. American Academy of Pediatrics, Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108(4):1033-1044.
18. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152(11):1652-1658.
19. Kollins SH, MacDonald EK, Cush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav. 2001;68(3):611-627.
20. Vitiello B. Long-term effects of stimulant medications on the brain: possible relevance to the treatment of attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001;11(1):25-34.
21. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil. 1998;31(6):533-544.
22. Barkley RA, Fischer M, Smallish L, Fletcher K. Does the treatment of ADHD with stimulant medication contribute to illicit drug use/abuse? a 13-year prospective study. Pediatrics. 2003;111(1):97-109.
23. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 1999;104(2):e20 http://pediatrics.aappublications. org/cgi/content/full/104/2/e20. ccessed June 24, 2008.
24. Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol. 2005;15(5):764-776.
25. Huss M. ADHD and substance abuse. In: IX Annual European Congress of Psychiatry. Hamburg, Germany. 1999.
26. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse: a meta-analytic review of the literature. Pediatrics. 2003;111(1):179-185.
27. Milberger S, Biederman J, Faraone SV, Wilens T, Chu MP. Associations between ADHD and psychoactive substance use disorders: findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict. 1997;6(4):318-329.
28. Biederman J, Faraone SV, Mick E, et al. Clinical correlates of ADHD in females: findings from a large group of girls ascertained from pediatric and psychiatric referral sources. J Am Acad Child Adolesc Psychiatry. 1999;38(8):966-975.
29. Disney ER, Elkins IJ, McGue M, Iacono WG. Effects of ADHD, conduct disorder, and gender on substance use and abuse in adolescence. Am J Psychiatry. 1999;156(10):1515-1521.
30. Huss M, Lehmkuhl U. Methylphenidate and substance abuse: a review of pharmacology, animal, and clinical studies. J Atten Disord. 2002;6(suppl 1):S65-S71.
31. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993;50(7):565-576.
32. Milberger S, Faraone SV, Biederman J, Chu MP, Wilens T. Familial risk analysis of the association between attention-deficit/hyperactivity disorder and psychoactive substance use disorders. Arch Pediatr Adolesc Med. 1998;152(10):945-951.
33. Wilens T. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk and treatment issues. In: Spencer T, ed. Psychiatric Clinics of North America. Philadelphia, PA: WB Saunders Co; 2004:283-301.
34. Monuteaux MC, Spencer TJ, Faraone SV, Wilson AM, Biederman J. A randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2007;68(7):1094-1101.
35. Robins LN. Deviant Children Grown Up. Baltimore, MD: Williams & Wilkins; 1966.
36. Biederman J, Monuteaux MC, Mick E, et al. Is cigarette smoking a gateway drug to subsequent alcohol and illicit drug use disorders? a controlled study of youths with and without ADHD. Biol Psychiatry. 2006;59(3):258-264.
37. Augustyniak PN, Kourrich S, Rezazadeh SM, Stewart J, Arvanitogiannis A. Differential behavioral and neurochemical effects of cocaine after early exposure to methylphenidate in an animal model of attention deficit hyperactivity disorder. Behav Brain Res. 2006;167(2):379-382.
38. Carlezon WA, Mague SD, Anderson SL. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry. 2003;54(12):1330-1337.
39. Gignac M, Wilens TE, Biederman J, Kwon A, Mick E, Swezey A. Assessing cannabis use in adolescents and young adults: what do urine screen and parental report tell you? J Child Adolesc Psychopharmacol. 2005;15(5):742-750.